99 results on '"Egeo A"'
Search Results
2. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures. The multicenter, prospective, real-life FRIEND2 study.
3. Association of LTA and SOD Gene Polymorphisms with Cerebral White Matter Hyperintensities in Migraine Patients
4. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
5. Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).
6. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
7. Discontinuing Monoclonal Antibodies Targeting CGRP Pathway After One-Year Treatment: An Observational Longitudinal Cohort Study
8. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study
9. Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study
10. Antioxidant and inflammatory polymorphism in patients with migraine with white matter hyperintensity (WMH)
11. Long-term (>48 weeks) safety and tolerability of erenumab in real-life
12. Project for the establishment of the Italian migraine registry(I-GRAINE-NEW)
13. Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations
14. Position Paper on the Applications of Ketogenic Diets in Patients with Headache: Consensus Statement
15. Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
16. Erenumab during pregnancy: a case report in a patient with chronic migraine
17. Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study
18. Migraineurs’ psychological traits do not influence response to erenumab
19. Migraine as a Cortical Brain Disorder
20. Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
21. Botulinum Neurotoxin for the Treatment of Neuropathic Pain
22. Erenumab during pregnancy: a case report in a patient with chronic migraine
23. Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients
24. New Evidence from the Italian chROnic migraiNe Registry (IRON Registry): An Update on 866 Patients (4117)
25. The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine (2307)
26. Machine learning approach to predict medication overuse in migraine patients
27. Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine
28. Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?
29. Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine
30. Does the migraine attack start in the cortex and is the cortex critical in the migraine process?
31. Erenumab: from scientific evidence to clinical practice—the first Italian real-life data
32. Pharmacotherapy for acute migraines in children and adolescents
33. Establishment of an Italian chronic migraine database: a multicenter pilot study
34. Predictors of response to onabotulinumtoxin A in chronic migraine
35. Procoagulant imbalance in premenopausal women with chronic migraine
36. Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study
37. Ketogenic diet in migraine: rationale, findings and perspectives
38. The role of anti-CGRP antibodies in the pathophysiology of primary headaches
39. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development
40. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study
41. The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients
42. Short-Term Non-Invasive Vagus Nerve Stimulation (nVNS) for the Prevention of Menstrual Migraine (P2.199)
43. Short-Term Non-Invasive Vagus Nerve Stimulation (nVNS) for the Prevention of Menstrual Migraine (I3.007)
44. A proposal for a national registry on chronic migraines
45. O039. Case-control genetic association studies in migraine: a 7-year experience at the Interinstitutional Multidisciplinary Biobank (BioBIM) of IRCCS San Raffaele Pisana
46. Chronic migraine: treatability, refractoriness, pseudo-refractoriness
47. O036. Cocaine and headache: a 2-year follow-up study in chronic cocaine users and literature review
48. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study
49. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine
50. Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.